Sophie Demeret
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Sophie Demeret has a total of 226 co-authors. Here are the top co-authors by number of shared publications:
- Aurélie Hanin
Institut du Cerveau ‐ Paris Brain Institute ‐ ICM, Inserm, CNRS, AP‐HP, Hôpital de la Pitié Salpêtrière, Sorbonne Université Paris France
8 shared publications - Vincent Navarro
Sorbonne Université, Paris Brain Institute - Institut du Cerveau, ICM, INSERM, CNRS, Pitié-Salpêtrière Hospital, France
8 shared publications - Clémence Marois
Neuro‐Intensive Care Unit AP‐HP, Sorbonne Université, Hôpital de la Pitié‐Salpêtrière Paris France
6 shared publications - Elizabeth E. Gerard
Feinberg School of Medicine Northwestern University Chicago Illinois USA
5 shared publications - Krista Eschbach
Section of Neurology, Department of Pediatrics University of Colorado School of Medicine, Children's Hospital Colorado Aurora Colorado USA
4 shared publications - Lawrence J. Hirsch
Department of Neurology Yale School of Medicine New Haven Connecticut USA
4 shared publications
Latest Publications
- Open Access
Longitudinal serum and CSF cytokine dynamics in NORSE : Associations with immunotherapy exposure
Objective: To characterize serum and cerebrospinal fluid (CSF) cytokine dynamics according to immunotherapy exposure in cryptogenic new‐onset refractory status epilepticus (cNORSE). Methods: We analyzed cytokine profiles in 94 serum and 42 CSF samples from 29 and 14 patients, respectively, with cNORSE. Nine contributed both sample types, resulting in 34 patients. Samples were categorized according to immunotherapy exposure as no immunotherapy (NT), first‐line (FL), and second‐line (SL), and stratified by innate‐ or adaptive‐directed therapies. SL represented cumulative exposure, as all SL samples followed initiation of both FL and SL therapies. Linear mixed‐effects models accounted for repeated measures and time from cNORSE onset. A systematic literature review included 27 studies and 63 patients. Results: Serum cytokine levels were generally lower during FL ( n = 24) than NT ( n = 9), whereas most cytokines were higher during SL ( n = 61) than FL. CXCL8 (C‐X‐C motif ligand 8)/IL‐8 and CCL2 (C‐C motif chemokine ligand 2) were higher during SL than FL, with CCL2 remaining significant after multiple‐testing correction. No serum differences remained significant when analyses were restricted to samples collected 7–30 days after onset. CSF levels were generally lower during FL ( n = 10) and SL ( n = 25) than NT ( n = 7). Innate‐directed therapies were associated with higher serum IL‐6, CXCL8/IL‐8, and CCL2 and CSF IL‐4, whereas adaptive‐directed therapies were associated with lower CSF MIP‐1α (Macrophage Inflammatory Protein‐1 alpha). The association with higher serum IL‐6 was no longer observed after excluding tocilizumab‐treated patients. No temporal association after SL initiation or status epilepticus resolution remained significant after multiple‐testing correction. The literature review showed more frequent reductions in pro‐inflammatory cytokines in CSF than serum following immunotherapy initiation. Significance: Cytokine profiles in cNORSE differ by treatment exposure and compartment. Persistent serum inflammation during SL may reflect disease severity, systemic inflammation, treatment effects, or their combination, whereas CSF showed more consistent reductions after immunotherapy exposure. These findings highlight the importance of treatment timing and compartment when interpreting cytokine measurements and support prospective studies integrating baseline immune phenotypes and standardized clinical outcomes.
Open AccessLongitudinal serum and CSF cytokine dynamics in NORSE : Associations with immunotherapy exposure
Objective: To characterize serum and cerebrospinal fluid (CSF) cytokine dynamics according to immunotherapy exposure in cryptogenic new‐onset refractory status epilepticus (cNORSE). Methods: We analyzed cytokine profiles in 94 serum and 42 CSF samples from 29 and 14 patients, respectively, with cNORSE. Nine contributed both sample types, resulting in 34 patients. Samples were categorized according to immunotherapy exposure as no immunotherapy (NT), first‐line (FL), and second‐line (SL), and stratified by innate‐ or adaptive‐directed therapies. SL represented cumulative exposure, as all SL samples followed initiation of both FL and SL therapies. Linear mixed‐effects models accounted for repeated measures and time from cNORSE onset. A systematic literature review included 27 studies and 63 patients. Results: Serum cytokine levels were generally lower during FL ( n = 24) than NT ( n = 9), whereas most cytokines were higher during SL ( n = 61) than FL. CXCL8 (C‐X‐C motif ligand 8)/IL‐8 and CCL2 (C‐C motif chemokine ligand 2) were higher during SL than FL, with CCL2 remaining significant after multiple‐testing correction. No serum differences remained significant when analyses were restricted to samples collected 7–30 days after onset. CSF levels were generally lower during FL ( n = 10) and SL ( n = 25) than NT ( n = 7). Innate‐directed therapies were associated with higher serum IL‐6, CXCL8/IL‐8, and CCL2 and CSF IL‐4, whereas adaptive‐directed therapies were associated with lower CSF MIP‐1α (Macrophage Inflammatory Protein‐1 alpha). The association with higher serum IL‐6 was no longer observed after excluding tocilizumab‐treated patients. No temporal association after SL initiation or status epilepticus resolution remained significant after multiple‐testing correction. The literature review showed more frequent reductions in pro‐inflammatory cytokines in CSF than serum following immunotherapy initiation. Significance: Cytokine profiles in cNORSE differ by treatment exposure and compartment. Persistent serum inflammation during SL may reflect disease severity, systemic inflammation, treatment effects, or their combination, whereas CSF showed more consistent reductions after immunotherapy exposure. These findings highlight the importance of treatment timing and compartment when interpreting cytokine measurements and support prospective studies integrating baseline immune phenotypes and standardized clinical outcomes.
Acute and Long‐Term EEG and seizure characteristics in new onset refractory status epilepticus (NORSE)
Objective: This study was undertaken to examine acute and chronic electroencephalographic (EEG) and seizure characteristics in new onset refractory status epilepticus (NORSE). Methods: Multicenter inpatient and follow‐up clinical and EEG data were analyzed using International League Against Epilepsy definitions and American Clinical Neurophysiology Society (ACNS) EEG terminology. Results: Forty‐four patients were included from the Yale NORSE/FIRES Biorepository (median age = 29 years, 33 female, 38 cryptogenic). Nine hundred twenty inpatient EEG days were reviewed (median = 13.5 days/patient). Presenting status epilepticus (SE) types included 24 convulsive SE (CSE), five focal–motor (FMSE), and 15 nonconvulsive (NCSE). Of 39 patients with post discharge follow‐up (median = 14.7 months), 61.5% ( n = 24) had seizures and required more antiseizure medications than seizure‐free patients (median = 4 vs. 1, p < .001). Inpatient EEG captured epileptiform discharges in all and periodic discharges in 38 patients. Seizures were captured in 38 patients: 33 electrographic (11 only electrographic) and 27 electroclinical. Total seizure burden ranged 6.5–29 615.0 min (median = 50.7). Seizures fulfilling ACNS EEG criteria for SE were captured in 20 patients; two had CSE and the remainder NCSE with coma, nine of whom also had FMSE. Inpatient seizure days (median = 50.0 vs. 15.5%, p = .004) and seizure burden (median = 42.9 vs. 0 min, p = .009) were higher in the first half of monitored days. Interictal findings were equally present and did not predict postdischarge seizures, whereas electroclinical seizures (90.9% vs. 45.5%, p = .037), seizure burden (median = 116.8 vs. 32.5 min, p = .045), and proportion of seizure days (36.3% vs. 20.0%, p = .037) did. Among 12 patients with follow‐up EEGs (median = 19.6 months post onset), posterior‐dominant rhythm (PDR) returned in nine; five had periodic discharges, and three had seizure captured. Significance: Seizures are most commonly convulsive upon presentation and nonconvulsive or clinically subtle throughout the inpatient course in NORSE. Inpatient seizures, but not interictal abnormalities, occur earlier in the inpatient course and presence of electroclinical seizures, seizure burden, and proportion of seizure days but not interictal findings are associated with postdischarge seizures. Although return of PDR reflects neurological recovery, seizure persistence and EEG abnormalities post‐NORSE are common.
Acute and Long‐Term EEG and seizure characteristics in new onset refractory status epilepticus (NORSE)
Objective: This study was undertaken to examine acute and chronic electroencephalographic (EEG) and seizure characteristics in new onset refractory status epilepticus (NORSE). Methods: Multicenter inpatient and follow‐up clinical and EEG data were analyzed using International League Against Epilepsy definitions and American Clinical Neurophysiology Society (ACNS) EEG terminology. Results: Forty‐four patients were included from the Yale NORSE/FIRES Biorepository (median age = 29 years, 33 female, 38 cryptogenic). Nine hundred twenty inpatient EEG days were reviewed (median = 13.5 days/patient). Presenting status epilepticus (SE) types included 24 convulsive SE (CSE), five focal–motor (FMSE), and 15 nonconvulsive (NCSE). Of 39 patients with post discharge follow‐up (median = 14.7 months), 61.5% ( n = 24) had seizures and required more antiseizure medications than seizure‐free patients (median = 4 vs. 1, p < .001). Inpatient EEG captured epileptiform discharges in all and periodic discharges in 38 patients. Seizures were captured in 38 patients: 33 electrographic (11 only electrographic) and 27 electroclinical. Total seizure burden ranged 6.5–29 615.0 min (median = 50.7). Seizures fulfilling ACNS EEG criteria for SE were captured in 20 patients; two had CSE and the remainder NCSE with coma, nine of whom also had FMSE. Inpatient seizure days (median = 50.0 vs. 15.5%, p = .004) and seizure burden (median = 42.9 vs. 0 min, p = .009) were higher in the first half of monitored days. Interictal findings were equally present and did not predict postdischarge seizures, whereas electroclinical seizures (90.9% vs. 45.5%, p = .037), seizure burden (median = 116.8 vs. 32.5 min, p = .045), and proportion of seizure days (36.3% vs. 20.0%, p = .037) did. Among 12 patients with follow‐up EEGs (median = 19.6 months post onset), posterior‐dominant rhythm (PDR) returned in nine; five had periodic discharges, and three had seizure captured. Significance: Seizures are most commonly convulsive upon presentation and nonconvulsive or clinically subtle throughout the inpatient course in NORSE. Inpatient seizures, but not interictal abnormalities, occur earlier in the inpatient course and presence of electroclinical seizures, seizure burden, and proportion of seizure days but not interictal findings are associated with postdischarge seizures. Although return of PDR reflects neurological recovery, seizure persistence and EEG abnormalities post‐NORSE are common.
- 14 April 2026
- Published by Elsevier in European Journal of Internal Medicine
- Vol. 150, 106878
Early brain biopsy in neurological diseases of unknown etiology improves functional outcome
- 14 April 2026
- Published by Elsevier in European Journal of Internal Medicine
- Vol. 150, 106878
Early brain biopsy in neurological diseases of unknown etiology improves functional outcome
- Open Access
Exploring pathways leading to drug‐resistant epilepsy for patients with cryptogenic new onset refractory status epilepticu s
Objective: Cryptogenic new onset refractory status epilepticus (cNORSE) carries high risks of long‐term disability and post‐NORSE epilepsy, but mechanisms remain unclear. We aimed to assess the predictive value of inflammatory and brain injury biomarkers and determine whether immune disturbances persist in the chronic phase. Methods: We enrolled 93 cNORSE patients from the Pitié‐Salpêtrière Hospital and the Yale NORSE/FIRES biorepository (2013–2025). Serum and cerebrospinal fluid (CSF) samples were collected during status epilepticus (SE), with outcomes assessed 6–12 months after resolution. To investigate post‐cNORSE epilepsy, we compared 39 post‐cNORSE patients (25 with paired acute samples) to 40 patients with temporal lobe epilepsy due to hippocampal sclerosis (TLE‐HS) and 20 with chronic immune‐mediated encephalitis. Results: During cNORSE, elevated innate cytokines (serum CXCL8, CCL2; CSF IL‐6, CXCL8, CCL2, MIP‐1α, G‐CSF) and brain injury biomarkers (serum and CSF neurofilament light chain [NfL], CSF neuron‐specific enolase) correlated with worse functional outcomes. Multivariate models demonstrated that adding serum NfL to cytokines improved poor outcome prediction (area under the curve = .75). In contrast, no acute biomarker predicted post‐cNORSE epilepsy, which was instead associated with prolonged SE, magnetic resonance imaging abnormalities, and the need for more intensive treatment. In paired analyses, most serum cytokines normalized during the chronic phase, particularly IL‐6, IL‐10, and IL‐1β, although new adaptive immune disturbances (IL‐17A, IL‐12p70, TNFα) appeared in 20% of patients. No chronic elevations of innate cytokines were observed in post‐cNORSE patients. Conversely, elevated age‐adjusted NfL levels were more frequent in post‐cNORSE epilepsy (64%) than encephalitis (45%) and TLE‐HS (20%), ( p < .001), with elevated NfL levels correlating with poor functional outcomes ( p = .019). Significance: Innate immune activation is a hallmark of acute cNORSE but largely resolves in the chronic phase, arguing against persistent innate inflammation as the driver of post‐cNORSE epilepsy. In contrast, persistently elevated NfL levels suggest ongoing axonal injury, potentially contributing to poor outcomes. Integrating inflammatory and neuroaxonal injury biomarkers may improve risk stratification and guide long‐term management.
Open AccessExploring pathways leading to drug‐resistant epilepsy for patients with cryptogenic new onset refractory status epilepticu s
Objective: Cryptogenic new onset refractory status epilepticus (cNORSE) carries high risks of long‐term disability and post‐NORSE epilepsy, but mechanisms remain unclear. We aimed to assess the predictive value of inflammatory and brain injury biomarkers and determine whether immune disturbances persist in the chronic phase. Methods: We enrolled 93 cNORSE patients from the Pitié‐Salpêtrière Hospital and the Yale NORSE/FIRES biorepository (2013–2025). Serum and cerebrospinal fluid (CSF) samples were collected during status epilepticus (SE), with outcomes assessed 6–12 months after resolution. To investigate post‐cNORSE epilepsy, we compared 39 post‐cNORSE patients (25 with paired acute samples) to 40 patients with temporal lobe epilepsy due to hippocampal sclerosis (TLE‐HS) and 20 with chronic immune‐mediated encephalitis. Results: During cNORSE, elevated innate cytokines (serum CXCL8, CCL2; CSF IL‐6, CXCL8, CCL2, MIP‐1α, G‐CSF) and brain injury biomarkers (serum and CSF neurofilament light chain [NfL], CSF neuron‐specific enolase) correlated with worse functional outcomes. Multivariate models demonstrated that adding serum NfL to cytokines improved poor outcome prediction (area under the curve = .75). In contrast, no acute biomarker predicted post‐cNORSE epilepsy, which was instead associated with prolonged SE, magnetic resonance imaging abnormalities, and the need for more intensive treatment. In paired analyses, most serum cytokines normalized during the chronic phase, particularly IL‐6, IL‐10, and IL‐1β, although new adaptive immune disturbances (IL‐17A, IL‐12p70, TNFα) appeared in 20% of patients. No chronic elevations of innate cytokines were observed in post‐cNORSE patients. Conversely, elevated age‐adjusted NfL levels were more frequent in post‐cNORSE epilepsy (64%) than encephalitis (45%) and TLE‐HS (20%), ( p < .001), with elevated NfL levels correlating with poor functional outcomes ( p = .019). Significance: Innate immune activation is a hallmark of acute cNORSE but largely resolves in the chronic phase, arguing against persistent innate inflammation as the driver of post‐cNORSE epilepsy. In contrast, persistently elevated NfL levels suggest ongoing axonal injury, potentially contributing to poor outcomes. Integrating inflammatory and neuroaxonal injury biomarkers may improve risk stratification and guide long‐term management.
- 1 December 2025
- Published by Wolters Kluwer Health in Neurology Clinical Practice
- Vol. 15 (6) , e200558
Diagnostic Yield of Next-Generation Sequencing in CSF or Brain Biopsy for Severe Encephalitis Requiring Intensive Care
The aim of this study was to evaluate the contribution of metagenomic next-generation sequencing (mNGS) in critically ill patients with encephalitis of unknown etiology. This retrospective study (2016-2023) was conducted in a tertiary care referral neuro-ICU at La Pitié-Salpêtrière Hospital (Paris, France). The inclusion criteria were encephalitis with unknown etiology and mNGS performed on CSF, brain biopsy, and/or autopsy. We assessed the yield of mNGS and whether specific treatments were initiated. Neurologic outcome at 1 year was assessed using the Glasgow Outcome Scale-Extended (GOSE-1: death; GOSE-8: upper good recovery). A total of 49 patients were included, of whom 44.9% were immunosuppressed. At 1 year, 38.8% had a GOSE score 4-8 and 47.7% died. mNGS was performed on the CSF of 40 of 49 patients (81.6%) and on brain biopsy of 19 of 49 patients (38.8%), including 12 patients who underwent both CSF and biopsy testing. Among the 40 mNGS analyses performed on the CSF, 7 (17.5%) yielded positive results but only 1 (2.5%) was likely causative. Conversely, 7 of 19 mNGS analyses (36.8%) on biopsies were positive and causative. Regarding the yield of mNGS in the entire cohort, 15 of 49 patients (30.6%) had a positive result but only 7 of 49 (14.3%) were causative (dengue virus, measles virus, rubella virus, Nocardia spp, HHV6, astrovirus, and orthobunyavirus), all from brain biopsies of immunocompromised patients. Conversely, 8 of 49 mNGS analyses (16.3%) were noncausative (polyomavirus, HHV8, HHV7, EBV, 2 pegiviruses, and 2 rhinoviruses). Specific treatments were initiated in 4 of 7 patients (57%). Among the 34 patients with a negative mNGS result, 5 (14.7%) were diagnosed with infectious encephalitis using conventional methods. In critically ill patients with encephalitis of unknown etiology, mNGS performed on brain biopsy could reduce diagnostic uncertainty.
- 1 December 2025
- Published by Wolters Kluwer Health in Neurology Clinical Practice
- Vol. 15 (6) , e200558
Diagnostic Yield of Next-Generation Sequencing in CSF or Brain Biopsy for Severe Encephalitis Requiring Intensive Care
The aim of this study was to evaluate the contribution of metagenomic next-generation sequencing (mNGS) in critically ill patients with encephalitis of unknown etiology. This retrospective study (2016-2023) was conducted in a tertiary care referral neuro-ICU at La Pitié-Salpêtrière Hospital (Paris, France). The inclusion criteria were encephalitis with unknown etiology and mNGS performed on CSF, brain biopsy, and/or autopsy. We assessed the yield of mNGS and whether specific treatments were initiated. Neurologic outcome at 1 year was assessed using the Glasgow Outcome Scale-Extended (GOSE-1: death; GOSE-8: upper good recovery). A total of 49 patients were included, of whom 44.9% were immunosuppressed. At 1 year, 38.8% had a GOSE score 4-8 and 47.7% died. mNGS was performed on the CSF of 40 of 49 patients (81.6%) and on brain biopsy of 19 of 49 patients (38.8%), including 12 patients who underwent both CSF and biopsy testing. Among the 40 mNGS analyses performed on the CSF, 7 (17.5%) yielded positive results but only 1 (2.5%) was likely causative. Conversely, 7 of 19 mNGS analyses (36.8%) on biopsies were positive and causative. Regarding the yield of mNGS in the entire cohort, 15 of 49 patients (30.6%) had a positive result but only 7 of 49 (14.3%) were causative (dengue virus, measles virus, rubella virus, Nocardia spp, HHV6, astrovirus, and orthobunyavirus), all from brain biopsies of immunocompromised patients. Conversely, 8 of 49 mNGS analyses (16.3%) were noncausative (polyomavirus, HHV8, HHV7, EBV, 2 pegiviruses, and 2 rhinoviruses). Specific treatments were initiated in 4 of 7 patients (57%). Among the 34 patients with a negative mNGS result, 5 (14.7%) were diagnosed with infectious encephalitis using conventional methods. In critically ill patients with encephalitis of unknown etiology, mNGS performed on brain biopsy could reduce diagnostic uncertainty.
- Open Access
An extreme type of new onset refractory status epilepticus with stimulus‐induced seizures in pharmacological isoelectric states
Objective: Status epilepticus (SE) is a common neurological emergency associated with high morbidity and mortality. SE is classified as refractory when it persists despite benzodiazepine and second‐line antiseizure medication. Managing refractory SE in the intensive care setting often requires high doses of sedative drugs, which can induce burst suppression or complete electrical suppression (amplitude < 10 μV). We aimed to investigate the characteristics of persistent epileptic seizures in patients undergoing pharmacologically induced electrical suppression for treatment of refractory SE. Methods: We retrospectively screened our hospital electroencephalographic (EEG) database for patients admitted to the neurointensive care unit with SE and a new onset refractory status epilepticus (NORSE) diagnosis from 2006 to 2024 ( N = 65). Patients with persistent seizures despite a suppressed EEG were included. EEG, biological, and clinical data and outcomes were collected. Results: We identified seven patients with persistent electrical seizures despite pharmacologically induced electrical suppression lasting >1 min. All had cryptogenic NORSE (c‐NORSE), preceded by a febrile event, and showed cerebrospinal fluid inflammation. Electrical suppression was achieved using three to four sedative drugs, including a barbiturate. A specific seizure onset EEG pattern was identified in all, characterized by periodic and/or rhythmic generalized discharges (GDs), followed by faster, lower amplitude rhythmic activity. In two patients, increased sedation revealed a second seizure onset pattern, characterized by abrupt rhythmic activity over isoelectric EEG background, independent of GDs. In six patients, multimodal stimuli (auditory, visual, or tactile) triggered either seizures, interictal high‐amplitude GDs, or both. Repeated stimuli were associated with small‐amplitude evoked potentials. All patients died in the intensive care unit. Significance: We report a series of seven c‐NORSE patients with a rare and extremely severe presentation: persistent and stimulus‐induced seizures occurring over an electrically suppressed EEG background. This hyperexcitability state may result from cellular and network alterations induced by phenobarbital in patients with central nervous system inflammation.
Open AccessAn extreme type of new onset refractory status epilepticus with stimulus‐induced seizures in pharmacological isoelectric states
Objective: Status epilepticus (SE) is a common neurological emergency associated with high morbidity and mortality. SE is classified as refractory when it persists despite benzodiazepine and second‐line antiseizure medication. Managing refractory SE in the intensive care setting often requires high doses of sedative drugs, which can induce burst suppression or complete electrical suppression (amplitude < 10 μV). We aimed to investigate the characteristics of persistent epileptic seizures in patients undergoing pharmacologically induced electrical suppression for treatment of refractory SE. Methods: We retrospectively screened our hospital electroencephalographic (EEG) database for patients admitted to the neurointensive care unit with SE and a new onset refractory status epilepticus (NORSE) diagnosis from 2006 to 2024 ( N = 65). Patients with persistent seizures despite a suppressed EEG were included. EEG, biological, and clinical data and outcomes were collected. Results: We identified seven patients with persistent electrical seizures despite pharmacologically induced electrical suppression lasting >1 min. All had cryptogenic NORSE (c‐NORSE), preceded by a febrile event, and showed cerebrospinal fluid inflammation. Electrical suppression was achieved using three to four sedative drugs, including a barbiturate. A specific seizure onset EEG pattern was identified in all, characterized by periodic and/or rhythmic generalized discharges (GDs), followed by faster, lower amplitude rhythmic activity. In two patients, increased sedation revealed a second seizure onset pattern, characterized by abrupt rhythmic activity over isoelectric EEG background, independent of GDs. In six patients, multimodal stimuli (auditory, visual, or tactile) triggered either seizures, interictal high‐amplitude GDs, or both. Repeated stimuli were associated with small‐amplitude evoked potentials. All patients died in the intensive care unit. Significance: We report a series of seven c‐NORSE patients with a rare and extremely severe presentation: persistent and stimulus‐induced seizures occurring over an electrically suppressed EEG background. This hyperexcitability state may result from cellular and network alterations induced by phenobarbital in patients with central nervous system inflammation.
- Open Access
Standard complete blood count to predict long‐term outcomes in febrile infection–related epilepsy syndrome (FIRES): A multicenter study
Objective: We investigated whether complete blood count (CBC) analyses during intensive care unit stay could predict 12‐month outcomes in patients with cryptogenic febrile infection–related epilepsy syndrome (FIRES), a subset of new‐onset refractory status epilepticus (NORSE). Methods: Outcomes at 12 months were classified as “unfavorable” (Glasgow Outcome Score [GOS] 1–3) or “favorable” (GOS 4–5). Demographic, clinical, and serial CBC data were collected across treatment phases: (1) no immunotherapy (before initiation or no treatment), (2) first‐line immunotherapy, and (3) second‐line immunotherapy. For each treatment phase, predictive models stratified outcomes based on CBC features using decision tree regression, with separate models for adults and children. Model performance was tested using a leave‐one‐patient‐out approach. Results: We studied 63 patients (34 adults, 29 children) from 12 centers. Unfavorable outcomes occurred in 18 adults and 12 children. Children were more likely to receive second‐line immunotherapy. We analyzed 1530 CBCs (adults: 997 CBCs, including 539 for unfavorable outcomes; children: 533 CBCs, including 415 for unfavorable outcomes). Subgroup analyses revealed differences in CBC levels according to the outcomes and the treatment received. Adults with unfavorable outcomes notably had higher neutrophil‐to‐lymphocyte ratios (NLRs) and monocyte‐to‐lymphocyte ratios (MLRs), whereas children with unfavorable outcomes had higher red cell distribution width. NLRs and MLRs increased when CBCs were collected after the initiation of immunotherapy for both adults and children. The variables of interest differed in the different predictive models but always included the proportion of at least one subtype of leukocyte. Prediction accuracy with our models was higher in children (87% overall, with the best performance in no‐treatment and first‐line phases) than in adults (83% overall, with the best performance during/after the initiation of second‐line). Significance: Findings suggest the potential for standard CBCs to serve as a rapid, accessible tool for early prognostication in cryptogenic FIRES, particularly in children.
Open AccessStandard complete blood count to predict long‐term outcomes in febrile infection–related epilepsy syndrome (FIRES): A multicenter study
Objective: We investigated whether complete blood count (CBC) analyses during intensive care unit stay could predict 12‐month outcomes in patients with cryptogenic febrile infection–related epilepsy syndrome (FIRES), a subset of new‐onset refractory status epilepticus (NORSE). Methods: Outcomes at 12 months were classified as “unfavorable” (Glasgow Outcome Score [GOS] 1–3) or “favorable” (GOS 4–5). Demographic, clinical, and serial CBC data were collected across treatment phases: (1) no immunotherapy (before initiation or no treatment), (2) first‐line immunotherapy, and (3) second‐line immunotherapy. For each treatment phase, predictive models stratified outcomes based on CBC features using decision tree regression, with separate models for adults and children. Model performance was tested using a leave‐one‐patient‐out approach. Results: We studied 63 patients (34 adults, 29 children) from 12 centers. Unfavorable outcomes occurred in 18 adults and 12 children. Children were more likely to receive second‐line immunotherapy. We analyzed 1530 CBCs (adults: 997 CBCs, including 539 for unfavorable outcomes; children: 533 CBCs, including 415 for unfavorable outcomes). Subgroup analyses revealed differences in CBC levels according to the outcomes and the treatment received. Adults with unfavorable outcomes notably had higher neutrophil‐to‐lymphocyte ratios (NLRs) and monocyte‐to‐lymphocyte ratios (MLRs), whereas children with unfavorable outcomes had higher red cell distribution width. NLRs and MLRs increased when CBCs were collected after the initiation of immunotherapy for both adults and children. The variables of interest differed in the different predictive models but always included the proportion of at least one subtype of leukocyte. Prediction accuracy with our models was higher in children (87% overall, with the best performance in no‐treatment and first‐line phases) than in adults (83% overall, with the best performance during/after the initiation of second‐line). Significance: Findings suggest the potential for standard CBCs to serve as a rapid, accessible tool for early prognostication in cryptogenic FIRES, particularly in children.
- Top Cited PapersOpen Access
- 1 July 2025
- Published by Wolters Kluwer Health in Neurology Neuroimmunology & Neuroinflammation
- Vol. 12 (4) , e200403
Identification of Distinct Biological Groups of Patients With Cryptogenic NORSE via Inflammatory Profiling
Emerging evidence suggests that immune dysregulation plays a pivotal role in triggering cryptogenic new-onset refractory status epilepticus (c-NORSE), prompting a consensus on early initiation of immunotherapy. However, despite similar timing of administration, responses to immunotherapies have been varied and unpredictable, suggesting the presence of heterogeneous underlying mechanisms. The aim of this study was to identify distinct inflammatory response subtypes in patients with c-NORSE by analyzing their cytokine profiles. Insights into underlying mechanisms were sought to understand the pathophysiology and guide personalized therapies to improve patient outcomes. Sixty-two patients with c-NORSE were included. A comprehensive panel of 96 cytokines was analyzed in serum samples. Patients were clustered based on their cytokine profiles using the Louvain algorithm, an unsupervised graph-based clustering method. The identified clusters of patients were compared regarding cytokine levels and clinical features. Protein pathway analysis was used to explore the biological relevance of the inflammatory markers within each cluster. Patients with c-NORSE were compared with control patients (n = 18) and patients with other forms of refractory SE (n = 45). Compared with controls, patients with c-NORSE exhibited significant differences in 33 cytokines. Pathway analysis revealed dysregulations in chemotaxis and neutrophil recruitment and migration, highlighting the importance of innate immunity in patients with c-NORSE. Within the c-NORSE cohort, 3 clusters of patients emerged: cluster A, lacking specific inflammatory markers; cluster B, with a much stronger innate-immunity cytokine-driven inflammatory response compared with clusters A and C; and cluster C, defined by dysregulated autoimmune processes. Notably, patients in cluster B showed a statistically significant elevation of innate immune-related proinflammatory cytokines associated with leukocyte recruitment and degranulation. By contrast, those in cluster C showed activation of Janus kinase signal transducer and activator of transcription (JAK-STAT) pathways, suggesting autoimmune mechanisms. Patients in clusters B and C demonstrated varied responses to immunotherapies, with cluster C patients showing favorable outcomes after multiple immunotherapies. The identification of distinct inflammatory subgroups in c-NORSE suggests that variations in the underlying immune mechanisms contribute to differential treatment responses. These findings underscore the importance of personalized therapeutic strategies, potentially targeting specific inflammatory pathways, to optimize clinical outcomes in this challenging condition.
- 1 July 2025
- Published by Wolters Kluwer Health in Neurology Neuroimmunology & Neuroinflammation
- Vol. 12 (4) , e200403
Top Cited PapersOpen AccessIdentification of Distinct Biological Groups of Patients With Cryptogenic NORSE via Inflammatory Profiling
Emerging evidence suggests that immune dysregulation plays a pivotal role in triggering cryptogenic new-onset refractory status epilepticus (c-NORSE), prompting a consensus on early initiation of immunotherapy. However, despite similar timing of administration, responses to immunotherapies have been varied and unpredictable, suggesting the presence of heterogeneous underlying mechanisms. The aim of this study was to identify distinct inflammatory response subtypes in patients with c-NORSE by analyzing their cytokine profiles. Insights into underlying mechanisms were sought to understand the pathophysiology and guide personalized therapies to improve patient outcomes. Sixty-two patients with c-NORSE were included. A comprehensive panel of 96 cytokines was analyzed in serum samples. Patients were clustered based on their cytokine profiles using the Louvain algorithm, an unsupervised graph-based clustering method. The identified clusters of patients were compared regarding cytokine levels and clinical features. Protein pathway analysis was used to explore the biological relevance of the inflammatory markers within each cluster. Patients with c-NORSE were compared with control patients (n = 18) and patients with other forms of refractory SE (n = 45). Compared with controls, patients with c-NORSE exhibited significant differences in 33 cytokines. Pathway analysis revealed dysregulations in chemotaxis and neutrophil recruitment and migration, highlighting the importance of innate immunity in patients with c-NORSE. Within the c-NORSE cohort, 3 clusters of patients emerged: cluster A, lacking specific inflammatory markers; cluster B, with a much stronger innate-immunity cytokine-driven inflammatory response compared with clusters A and C; and cluster C, defined by dysregulated autoimmune processes. Notably, patients in cluster B showed a statistically significant elevation of innate immune-related proinflammatory cytokines associated with leukocyte recruitment and degranulation. By contrast, those in cluster C showed activation of Janus kinase signal transducer and activator of transcription (JAK-STAT) pathways, suggesting autoimmune mechanisms. Patients in clusters B and C demonstrated varied responses to immunotherapies, with cluster C patients showing favorable outcomes after multiple immunotherapies. The identification of distinct inflammatory subgroups in c-NORSE suggests that variations in the underlying immune mechanisms contribute to differential treatment responses. These findings underscore the importance of personalized therapeutic strategies, potentially targeting specific inflammatory pathways, to optimize clinical outcomes in this challenging condition.
- Open Access
- 1 May 2024
- Published by Wolters Kluwer Health in Neurology Neuroimmunology & Neuroinflammation
- Vol. 11 (3) , e200229
Comparative Study of Paraneoplastic and Nonparaneoplastic Autoimmune Encephalitis With GABA B R Antibodies
While patients with paraneoplastic autoimmune encephalitis (AE) with gamma-aminobutyric-acid B receptor antibodies (GABABR-AE) have poor functional outcomes and high mortality, the prognosis of nonparaneoplastic cases has not been well studied. Patients with GABABR-AE from the French and the Dutch Paraneoplastic Neurologic Syndromes Reference Centers databases were retrospectively included and their data collected; the neurologic outcomes of paraneoplastic and nonparaneoplastic cases were compared. Immunoglobulin G (IgG) isotyping and human leukocyte antigen (HLA) genotyping were performed in patients with available samples. A total of 111 patients (44/111 [40%] women) were enrolled, including 84 of 111 (76%) paraneoplastic and 18 of 111 (16%) nonparaneoplastic cases (cancer status was undetermined for 9 patients). Patients presented with seizures (88/111 [79%]), cognitive impairment (54/111 [49%]), and/or behavioral disorders (34/111 [31%]), and 54 of 111 (50%) were admitted in intensive care unit (ICU). Nonparaneoplastic patients were significantly younger (median age 54 years [range 19-88] vs 67 years [range 50-85] for paraneoplastic cases, p < 0.001) and showed a different demographic distribution. Nonparaneoplastic patients more often had CSF pleocytosis (17/17 [100%] vs 58/78 [74%], p = 0.02), were almost never associated with KTCD16-abs (1/16 [6%] vs 61/70 [87%], p < 0.001), and were more frequently treated with second-line immunotherapy (11/18 [61%] vs 18/82 [22%], p = 0.003). However, no difference of IgG subclass or HLA association was observed, although sample size was small (10 and 26 patients, respectively). After treatment, neurologic outcome was favorable (mRS ≤2) for 13 of 16 (81%) nonparaneoplastic and 37 of 84 (48%) paraneoplastic cases (p = 0.03), while 3 of 18 (17%) and 42 of 83 (51%) patients had died at last follow-up (p = 0.008), respectively. Neurologic outcome no longer differed after adjustment for confounding factors but seemed to be negatively associated with increased age and ICU admission. A better survival was associated with nonparaneoplastic cases, a younger age, and the use of immunosuppressive drugs. Nonparaneoplastic GABABR-AE involved younger patients without associated KCTD16-abs and carried better neurologic and vital prognoses than paraneoplastic GABABR-AE, which might be due to a more intensive treatment strategy. A better understanding of immunologic mechanisms underlying both forms is needed.
- 1 May 2024
- Published by Wolters Kluwer Health in Neurology Neuroimmunology & Neuroinflammation
- Vol. 11 (3) , e200229
Open AccessComparative Study of Paraneoplastic and Nonparaneoplastic Autoimmune Encephalitis With GABA B R Antibodies
While patients with paraneoplastic autoimmune encephalitis (AE) with gamma-aminobutyric-acid B receptor antibodies (GABABR-AE) have poor functional outcomes and high mortality, the prognosis of nonparaneoplastic cases has not been well studied. Patients with GABABR-AE from the French and the Dutch Paraneoplastic Neurologic Syndromes Reference Centers databases were retrospectively included and their data collected; the neurologic outcomes of paraneoplastic and nonparaneoplastic cases were compared. Immunoglobulin G (IgG) isotyping and human leukocyte antigen (HLA) genotyping were performed in patients with available samples. A total of 111 patients (44/111 [40%] women) were enrolled, including 84 of 111 (76%) paraneoplastic and 18 of 111 (16%) nonparaneoplastic cases (cancer status was undetermined for 9 patients). Patients presented with seizures (88/111 [79%]), cognitive impairment (54/111 [49%]), and/or behavioral disorders (34/111 [31%]), and 54 of 111 (50%) were admitted in intensive care unit (ICU). Nonparaneoplastic patients were significantly younger (median age 54 years [range 19-88] vs 67 years [range 50-85] for paraneoplastic cases, p < 0.001) and showed a different demographic distribution. Nonparaneoplastic patients more often had CSF pleocytosis (17/17 [100%] vs 58/78 [74%], p = 0.02), were almost never associated with KTCD16-abs (1/16 [6%] vs 61/70 [87%], p < 0.001), and were more frequently treated with second-line immunotherapy (11/18 [61%] vs 18/82 [22%], p = 0.003). However, no difference of IgG subclass or HLA association was observed, although sample size was small (10 and 26 patients, respectively). After treatment, neurologic outcome was favorable (mRS ≤2) for 13 of 16 (81%) nonparaneoplastic and 37 of 84 (48%) paraneoplastic cases (p = 0.03), while 3 of 18 (17%) and 42 of 83 (51%) patients had died at last follow-up (p = 0.008), respectively. Neurologic outcome no longer differed after adjustment for confounding factors but seemed to be negatively associated with increased age and ICU admission. A better survival was associated with nonparaneoplastic cases, a younger age, and the use of immunosuppressive drugs. Nonparaneoplastic GABABR-AE involved younger patients without associated KCTD16-abs and carried better neurologic and vital prognoses than paraneoplastic GABABR-AE, which might be due to a more intensive treatment strategy. A better understanding of immunologic mechanisms underlying both forms is needed.